All News
Filter News
Found 41 articles
-
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
-
First patient in treatment in RhoVac's clinical phase IIb study in United Kingdom
1/7/2021
RhoVac AB ("RhoVac") announces today, on January 7th, 2021, that the first patient in United Kingdom is enrolled in the company's clinical phase IIb study in prostate cancer, a study named RhoVac-002 ("BRaVac").
-
RhoVac's Prostate Cancer Drug Candidate, RV001, is granted Fast Track Designation by the FDA
11/25/2020
RhoVac, a clinical stage company announced that the American FDA has granted Fast Track Designation to the company's drug candidate, RV001.
-
Clinical Catch-Up: November 9-13
11/16/2020
It was a particularly busy week for clinical trial updates, mostly because of several virtual conferences, including the virtual American Heart Association Scientific Sessions 2020 and The Society for Immunotherapy of Cancer’s Annual Meetings. Here's a look. -
RhoVac Participates in BIO Europe Digital
10/26/2020
RhoVac AB announces that it is participating this week in the partnering event BIO Europe 2020 Digital.
-
Article on RhoVac's Phase I/II study to be published in November 2020
10/26/2020
RhoVac AB announces that the publication of the article on RhoVac's Phase I/II study is set to be published in November.
-
The Covid-19 pandemic is expected to further affect RhoVac's clinical phase IIb study
10/12/2020
RhoVac AB announces that the company's clinical phase IIb study in prostate cancer, a multi-center study with the designation RhoVac-002, is expected to be further delayed due to the prevailing Covid-19 pandemic.
-
BioSpace Movers & Shakers, Sept. 11
9/11/2020
Biopharma and life sciences companies bolster their leadership teams and boards with these Movers & Shakers. -
RhoVac appoints Professor Georg Holländer to its Scientific Advisory Board
9/4/2020
RhoVac AB ("RhoVac") announces today September 4 th 2020, that it is continuing to strengthen the Scientific Advisory Board with a pediatric immunologist, by appointing Professor Georg Holländer , Action Research Professor and Head of Department at Oxford University , UK and Professor in Development Immunology, ETH Zurich, Sw
-
BioSpace Global Roundup, Aug. 13
8/13/2020
Biopharma and life sciences companies from across the globe provide updates on their business and pipelines. -
First patient in treatment in RhoVac's clinical phase IIb study in the USA
8/10/2020
RhoVac AB announces , August 10th 2020, that the first patient in the USA is included in the company's clinical phase IIb study in prostate cancer, a study entitled RhoVac-002.
-
A RhoVac Article is Published in the June Edition of MedNous, a Publication of Evernow Publishing Ltd
7/1/2020
RhoVac AB ("RhoVac") is published in the June edition of MedNous, through a written commentary by CEO Anders Månsson.
-
First Patient in Treatment in RhoVac's Clinical Phase IIb Study in Germany
4/23/2020
RhoVac AB ("RhoVac") announces today, on 23rd April 2020, that the first patient in Germany is in treatment in the company's clinical phase IIb study in prostate cancer, a study entitled RhoVac-002 ("BRaVac").
-
Covid-19 Related Delays in the Ongoing Phase IIb-study are Expected to be Managed With Existing Funding
4/2/2020
RhoVac AB announces, on April 2 2020, that the company is now seeing signs of delays in the ongoing clinical phase IIb study with the drug candidate RV001 in prostate cancer, due to the Covid-19 pandemic.
-
First Patient in Treatment for RhoVac's Clinical Phase II Study in Finland
3/3/2020
RhoVac AB announces, on 3rd March 2020, that the first patient in Finland has started treatment in the company's clinical phase IIb study in prostate cancer, a study entitled RhoVac-002.
-
RhoVac Announces Appointment of Professor Anne J. Ridley to its Scientific Advisory Board
2/6/2020
RhoVac AB announces, 6th February 2020, the appointment of a leading oncology expert to its Scientific Advisory Board with the addition of Anne J. Ridley, PhD, Professor of Cell Biology and Head of School of Cellular and Molecular Medicine, University of Bristol, UK.
-
RhoVac Receives Approval in Germany and Belgium to Start Clinical Phase IIb Study in Prostate Cancer
1/10/2020
RhoVac AB ("RhoVac") announces today, on 10th January 2020, that the company has received approval from Beligian FAMHP (Federal Agency for Medicines and Health Products) and German Federal Institute for Vaccines and Biomedicines for starting the clinical phase IIb study in prostate cancer, a multicenter study entitled RhoVac-002 ("BRaVac").
-
RhoVac Reports Interim Results on Immunological Response with RV001
11/18/2019
Today, 18th November 2019, RhoVac AB reports interim results from ongoing immunological studies at University of Tübingen, Germany concluding that treatment with RV001 can activate CD4+ T-cells and also CD8+ T-cells.
-
First Patient Screened for RhoVac's Clinical Phase IIb-study
11/4/2019
RhoVac AB announces, on 4th November 2019, that the first patient has been screened for the company's clinical phase IIb study in prostate cancer, a study entitled RhoVac-002 The screening took place at the Odense University Hospital.
-
Gunnar Gårdemyr New Chairman of the Board of RhoVac
10/30/2019
RhoVac AB announces, 30th October 2019, that Mikael Ørum will leave the board and the chair of the board, Gunnar Gårdemyr, who was elected to the board in May 2018, takes over as the chairman of the board.